RESUMO
Enzyme-based therapy has garnered significant attention for its current applications in various diseases. Despite the notable advantages associated with the use of enzymes as therapeutic agents, that could have high selectivity, affinity, and specificity for the target, their application faces challenges linked to physico-chemical and pharmacological properties. These limitations can be addressed through the encapsulation of enzymes in nanoplatforms as a comprehensive solution to mitigate their degradation, loss of activity, off-target accumulation, and immunogenicity, thus enhancing bioavailability, therapeutic efficacy, and circulation time, thereby reducing the number of administrations, and ameliorating patient compliance. The exploration of novel nanomedicine-based enzyme therapeutics for the treatment of challenging diseases stands as a paramount goal in the contemporary scientific landscape, but even then it is often not enough. Combining an enzyme with another therapeutic (e.g., a small molecule, another enzyme or protein, a monoclonal antibody, or a nucleic acid) within a single nanocarrier provides innovative multidrug-integrated therapy and ensures that both the actives arrive at the target site and exert their therapeutic effect, leading to synergistic action and superior therapeutic efficacy. Moreover, this strategic approach could be extended to gene therapy, a field that nowadays has gained increasing attention, as enzymes acting at genomic level and nucleic acids may be combined for synergistic therapy. This multicomponent therapeutic approach opens opportunities for promising future developments. This article is categorized under: Therapeutic Approaches and Drug Discovery > Nanomedicine for Neurological Disease Therapeutic Approaches and Drug Discovery > Nanomedicine for Oncologic Disease Therapeutic Approaches and Drug Discovery > Emerging Technologies.
Assuntos
Terapia Enzimática , Nanomedicina , Humanos , AnimaisRESUMO
In recent years, enzyme therapy strategies have rapidly evolved to catalyze essential biochemical reactions with therapeutic potential. These approaches hold particular promise in addressing rare genetic disorders, cancer treatment, neurodegenerative conditions, wound healing, inflammation management, and infectious disease control, among others. There are several primary reasons for the utilization of enzymes as therapeutics: their substrate specificity, their biological compatibility, and their ability to generate a high number of product molecules per enzyme unit. These features have encouraged their application in enzyme replacement therapy where the enzyme serves as the therapeutic agent to rectify abnormal metabolic and physiological processes, enzyme prodrug therapy where the enzyme initiates a clinical effect by activating prodrugs, and enzyme dynamic or starving therapy where the enzyme acts upon host substrate molecules. Currently, there are >20 commercialized products based on therapeutic enzymes, but approval rates are considerably lower than other biologicals. This has stimulated nanobiotechnology in the last years to develop nanoparticle-based solutions that integrate therapeutic enzymes. This approach aims to enhance stability, prevent rapid clearance, reduce immunogenicity, and even enable spatio-temporal activation of the therapeutic catalyst. This comprehensive review delves into emerging trends in the application of therapeutic enzymes, with a particular emphasis on the synergistic opportunities presented by incorporating enzymes into nanomaterials. Such integration holds the promise of enhancing existing therapies or even paving the way for innovative nanotherapeutic approaches.
Assuntos
Terapia Enzimática , Nanoestruturas , Humanos , Terapia Enzimática/métodos , Animais , Nanoestruturas/química , Enzimas/administração & dosagem , Enzimas/metabolismo , Enzimas/química , Pró-Fármacos/administração & dosagem , Pró-Fármacos/uso terapêutico , Terapia de Reposição de Enzimas/métodosRESUMO
Glucose oxidase (GOx)-based enzyme therapeutics are potential alternatives for colorectal cancer (CRC) treatment via glucose consumption and accumulation of hydrogen peroxide (H2O2). Given that H2O2 can be eliminated by cytoprotective autophagy, autophagy inhibitors that can interrupt autolysosome-induced H2O2 elimination are promising combination drugs of GOx. Here, we developed a multifunctional biomimetic nanocarrier for effective co-delivery of an autophagy inhibitor-chloroquine phosphate (CQP) and GOx to exert their synergistic effect by irreversibly upregulating intracellular reactive oxygen species (ROS) levels. Poly (D, l-lactide-co-glycolide) (PLGA) nanoparticles (NPs) were used to encapsulate both GOx and CQP using a W/O/W multi-emulsion method. Calcium phosphate (CaP) was used to "fix" CQP to GOx in the internal water phase, where it served as a pH-sensitive unit to facilitate intracellular drug release. Folic acid-modified red blood cell membranes (FR) were used to camouflage the GOx/CQP/CaP encapsulated PLGA NPs (referred to as PLGA/GCC@FR). In an AOM/DSS-induced CRC mouse model, PLGA/GCC@FR exhibited improved antitumor effects, in which the number of tumor nodes were only a quarter of that in the free drug combination group. The enhanced therapeutic effects of PLGA/GCC@FR were attributed to the prolonged tumor retention which was verified by both dynamic in vivo imaging and drug biodistribution. This multifunctional biomimetic nanocarrier facilitated combined enzyme therapeutics by depleting glucose and augmenting intracellular ROS levels in tumor cells, which exerted a synergistic inhibitory effect on tumor growth. Therefore, this study proposed a novel strategy for the enhancement of combined enzyme therapeutics, which provided a promising method for effective CRC treatment.
Assuntos
Neoplasias Colorretais , Nanopartículas , Neoplasias , Animais , Camundongos , Óxidos , Glucose/metabolismo , Biomimética , Peróxido de Hidrogênio/metabolismo , Espécies Reativas de Oxigênio , Distribuição Tecidual , Neoplasias/metabolismo , Copolímero de Ácido Poliláctico e Ácido Poliglicólico/metabolismo , Terapia Enzimática , Neoplasias Colorretais/tratamento farmacológico , Glucose Oxidase , Linhagem Celular TumoralRESUMO
Papillary subtypes of renal-cell carcinoma (pRCC) represent 10-15% of the cases and commonly have MET alterations. This systematic review and single-arm meta-analysis evaluated MET inhibitor therapy (METi) efficacy and safety in adults with confirmed advanced pRCC. The search strategy included PubMed, Web-of-science, Cochrane, and Scopus. We used the DerSimonian/Laird random effect model for all analyses; p-value < 5% was considered significant, and heterogeneity was assessed with I2. Three clinical trials and six cohort studies were included with 504 patients; 31% were MET-driven. Our pooled analysis demonstrated an objective response rate (ORR) in MET-driven, MET-independent, and overall patients of: 36% (95%CI: 10-62), 0% (95%CI: 0-3), and 21% (95%CI: 1-41), respectively. One-year disease control and progression-free survival rates were, respectively, 70% (95%CI: 52-88) and 15% (95%CI: 10-20). Twelve- and twenty-four-month survival rates were, respectively, 43% (95%CI: 23-64) and 10% (95%CI: 0-30). The prevalence of adverse events of any grade and grades 3-5 were 96% (95%CI: 91-100) and 44% (95%CI: 37-50), respectively. We suggest METi has anti-tumor activity and is tolerable in patients with advanced pRCC.
Assuntos
Carcinoma de Células Renais , Neoplasias Renais , Adulto , Humanos , Carcinoma de Células Renais/tratamento farmacológico , Carcinoma de Células Renais/patologia , Estudos de Coortes , Terapia Enzimática , Neoplasias Renais/patologia , Inibidores de Proteínas Quinases/efeitos adversosRESUMO
BACKGROUND: Alcohol and tobacco are important risk factors for chronic pancreatitis (CP). AIM: To analyze the effect of etiological factors such as tobacco and alcohol and pancreatic enzyme replacement therapy (PERT) in the progression of CP. MATERIAL AND METHODS: Patients with a diagnosis of CP were recruited and grouped according to variables such as tobacco, alcohol and PERT. They were followed for 18 months. Subsequently, different variables and analytical parameters involved in the progression of the disease were analyzed. RESULTS: A total of 50 patients diagnosed with CP were included. Of these, 28 patients underwent PERT, 39 were smokers and 33 were alcohol users. Compared with patients without PERT, those with PERT had a higher proportion of diabetes (64 and 32%, respectively), had a higher need for endoscopic treatment (25 and 0%, respectively) and a normal body mass index (71 and 27.3%, respectively. The smokers had higher calcium levels and increased lymphocytosis and leukocytosis. The alcohol consumption group had a higher mean age (p = 0.04) CONCLUSIONS: PERT may improve the nutritional status but does not reduce the need for endoscopic or surgical treatment. Smoking and alcohol consumption favored the progression of CP. Also, smoking induced a pro-inflammatory state.
Assuntos
Humanos , Masculino , Feminino , Adulto , Pessoa de Meia-Idade , Idoso , Pancreatite Crônica/etiologia , Pancreatite Crônica/terapia , Pancreatite Crônica/epidemiologia , Pâncreas , Insuficiência Pancreática Exócrina/etiologia , Insuficiência Pancreática Exócrina/terapia , Nicotiana/efeitos adversos , Consumo de Bebidas Alcoólicas/efeitos adversos , Fatores de Risco , Distribuição por Sexo , Progressão da Doença , Terapia EnzimáticaRESUMO
Resumen: El propósito de este artículo es proponer un marco bioético para la administración de la terapia enzimática en niños con enfermedad de Fabry asintomáticos. Se realizó un estudio de campo transversal, observacional, descriptivo, con análisis cuantitativo y cualitativo, a la luz de la bioética en médicos que han diagnosticado y tratado pacientes con la enfermedad a nivel nacional e internacional, mediante una encuesta con preguntas cerradas validada por juicio de expertos, se evaluó la aplicación de los principios de no maleficencia, justicia y sacralidad de la vida en la administración del tratamiento enzimático para estos pacientes. La información se agrupó y procesó con estadística descriptiva. El 83,33 % de los encuestados consideró que un niño con enfermedad de Fabry asintomático debe recibir tratamiento enzimático específico, independientemente de su costo (justicia), además, que el tratamiento debe ser financiado por el Estado a fin de prevenir las complicaciones de la enfermedad; esto fue reconocido por el 75 % de los médicos encuestados (no maleficencia). El 66,66 % consideró que la sacralidad de la vida está en función de prevenir las complicaciones que condicionan la muerte. Así, con base en la bioética principialista se justifica iniciar la terapia enzimática específica para el tratamiento de niños con enfermedad de Fabry asintomáticos.
Abstract: This paper aims to propose a bioethical framework for the administration of enzyme therapy in children with asymptomatic Fabry disease. A cross-sectional, observational, descriptive field study was conducted with quantitative and qualitative analysis, in the light of bioethics with physicians who have diagnosed and treated patients with classic Fabry disease at the local and international level, using a survey with closed questions validated by expert judgment. The application of the principles of non-maleficence, justice, and sacredness of life in the administration of enzymatic treatment for these patients was evaluated. The information was grouped and processed with descriptive statistics. 83,33 % of respondents considered that a child with asymptomatic Fabry disease should receive specific enzymatic treatment, regardless of its cost (justice), and that treatment should be funded by the State in order to prevent complications of the disease. This was recognized by 75% of the physicians surveyed (not maleficence). 66,66 % considered that the sacredness of life must prevent the complications that condition death. Thus, based on the principles of bioethics, initiating specific enzymatic therapy for the treatment of children with asymptomatic Fabry disease is sustained.
Resumo: o propósito deste artigo é propor um referencial bioético para administrar a terapia enzimática em crianças com doença de Fabry assintomáticos. Foi realizado um estudo de campo transversal, observacional, descritivo, com análise quantitativa e qualitativa, à luz da bioética em médicos que diagnosticaram e trataram pacientes com a doença no contexto nacional e internacional, mediante questionário com perguntas fechadas validada porjulga- mento de especialistas; foi avaliada a aplicação dos princípios de não maleficência, justiça e sacralidade da vida na administração do tratamento enzimático para esses pacientes. A informação foi agrupada e processada com estatística descritiva. 83,33 % dos pesquisados consideraram que uma criança com doença de Fabry assintomática deve receber tratamento enzimático específico, independentemente de seu custo (justiça), além disso que o tratamento deve ser financiado pelo Estado para prevenir as complicações da doença. Isso foi reconhecido por 75 % dos médicos investigados (não maleficência). 66,66 % consideraram que a sacralidade da vida está em função de prevenir as complicações que condicionam a morte. Assim, com base na bioética principialista, justifica-se iniciar a terapia enzimática específica para tratar crianças com doença de Fabry assintomáticas.
Assuntos
Humanos , Bioética , Pediatria , Doença de Fabry , Terapia EnzimáticaRESUMO
ExoU, uma citotoxina produzida pelo patógeno oportunista Pseudomonas aeruginosa e translocada para o citosol de células hospedeiras via sistema de secreção do tipo III, é associada à gravidade de infecções agudas. No presente trabalho, o efeito de ExoU na ativação do estresse oxidativo e da resposta antioxidante foi avaliado em culturas de células epiteliais respiratórias humanas infectadas com a cepa PA103 de P. aeruginosa (produtora de ExoU), com a mutante deletada no gene exoU, PA103∆exoU, ou com a mutante complementada com exoU sem atividade tipo fosfolipase A2, PA103∆UT/S142A. Análises das dosagens de hidroperóxidos lipídicos e isoprostanos, considerados marcadores de estresse oxidativo, revelaram que ExoU promoveu um aumento em suas concentrações. Foi observado, também, que ExoU estimulou a produção de espécies reativas de oxigênio, óxido nítrico e peroxinitrito nas células infectadas, assim como a expressão de iNOS e eNOS, mas não de nNOS. Além disso, ExoU foi responsável pelo aumento da atividade de SOD1 e pela redução dos níveis de GSH, mas não afetou a atividade da catalase ou de NQO1. No modelo in vivo, a dosagem de malondialdeído, um subproduto da lipoperoxidação de membranas, evidenciou uma maior produção deste composto no pulmão de camundongos infectados pela cepa produtora de ExoU, em comparação ao pulmão de camundongos infectados pela cepa mutante. Em conjunto, estes resultados mostram que ExoU ativa a produção de espécies reativas de oxigênio e nitrogênio, levando à peroxidação lipídica e modulando o sistema de defesa antioxidante...
ExoU, a cytotoxin produced by the opportunistic pathogen Pseudomonas aeruginosa and translocated into the cytosol of host cells via a type III secretion system, is associated with severity of acute infections. In the present work, the effect of ExoU in the activation of oxidative stress and antioxidant response was evaluated in cultures of human respiratory epithelial cells infected with P. aeruginosa PA103 strain (producer of ExoU), or with its isogenic mutants, the ExoU-deficient PA103∆exoU or the exoU-depleted mutant complemented with an exoU gene with a site-specific mutation in the PLA2 catalytic site, PA103∆UT/S142A. Analysis of dosages of lipid hydroperoxides and isoprostanes, considered markers of oxidative stress, revealed that ExoU promoted an increase in their concentrations. It was also observed that ExoU stimulated the production of reactive oxygen species, nitric oxide and peroxynitrite in infected cells, as well as the expression of iNOS and eNOS, but not nNOS. Furthermore, ExoU was responsible for the increased activity of SOD1 and the reduced levels of GSH, but did not affect the activity of catalase or NQO1. In the in vivo model, the analysis of malondialdehyde, a byproduct of lipid peroxidation of membranes, showed increased production of this compound in the lungs of mice infected with the ExoU-producing strain compared to the lungs of mice infected with the mutant strain. Together, these results show that ExoU activates the production of reactive oxygen and nitrogen species, leading to lipid peroxidation and modulating the antioxidant defense system...
Assuntos
Humanos , Animais , Citotoxinas , Estresse Oxidativo , Pseudomonas aeruginosa/patogenicidade , Proteínas de Bactérias , Terapia Enzimática , Células Epiteliais , Pseudomonas aeruginosa/genéticaRESUMO
Chronic pancreatitis occurs by the prolonged inflammation of pancreatic tissue that induces the irreversible destruction of the organ, leading to a global pancreatic insufficiency. The most common manifestations are abdominal pain, diarrhea, malabsorption, and possibly diabetes mellitus. Chronic pancreatitis treatment includes dietary restrictions, enzymatic supplementation, vitamins, and endoscopic or surgical methods depending on the degree of ductal involvement. In addition to the known therapies, new therapies are under development and research.
La pancreatitis crónica se desarrolla por la inflamación prolongada del tejido pancreático que induce la destrucción irreversible del órgano, llevando a una insuficiencia pancreática global. Las manifestaciones más frecuentes son dolor abdominal, diarrea, malabsorción y eventualmente diabetes mellitus. El tratamiento en pancreatitis crónica incluye restricciones dietarias, suplementación enzimática, vitamínica, y métodos endoscópicos o quirúrgicos, dependiendo del grado de compromiso ductal. Además de lo descrito, están en desarrollo y experimentación nuevas terapias.